Last reviewed · How we verify
NCT00471263
The Effects of Casigold and Casimax on Blood Pressure in Subjects With Highnormal Blood Pressure or Mild Hypertension
NA trial testing Casigold in Blood Pressure in 84 participants. Completed in 1 February 2008.
18 December 2007
Quick facts
| Lead sponsor | TNO |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 84 |
| Start date | 7 May 2007 |
| Primary completion | 18 December 2007 |
| Estimated completion | 1 February 2008 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
Conditions studied
- Blood Pressure — all drugs for Blood Pressure →
Sponsor
TNO — full company profile →
Who can join
Adults 30 to 70, any sex, with Blood Pressure. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Blood pressure
Time frame: 4 weeks
Sponsor's own description
The primary purpose of the study is to demonstrate a blood pressure lowering effect of CasiGold and CasiMax in subjects with high-normal blood pressure or mild hypertension. The secondary purpose is to collect human safety data after treatment with CasiGold and CasiMax, to gain insight into potential mechanisms by measurement of renin and angiotensin I and II, and to evaluate the genetic determinants of the individual BP lowering response by measurement of specific genetic polymorphisms.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
IPP-rich milk protein hydrolysate lowers blood pressure in subjects with stage 1 hypertension, a randomized controlled trial.
Boelsma E, Kloek J. · · 2010 · cited 37× · PMID 21059213 · DOI 10.1186/1475-2891-9-52
Verify or expand the search:
- PubMed search for NCT00471263
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Blood Pressure
Currently open trials in the same condition.
- NCT07070583 — Impact of Aorto-Iliac Occlusive Disease Treatment on Blood Pressure · NA · recruiting
- NCT07396636 — Machine Learning-Assisted Management of Intraoperative Hypotension for Personalized Treatment · recruiting
- NCT06719518 — Performance Evaluation of the ViTrack Continuous Non-invasive Blood Pressure Measurement Device · recruiting
- NCT07319117 — Evaluation of the Impact of a Nutritional Formulation on Cognitive Performance Following Stress Exposure. · NA · recruiting
- NCT06837181 — Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM) · recruiting
Other TNO trials
Trials by the same sponsor.
- NCT06236334 — ELFI Health (e-Health for Empowerment by Lifestyle, Food Advice and Interaction) · NA · completed
- NCT06547983 — Effectiviteit en Beleving Van FooDIYou · NA · completed
- NCT07459140 — Evaluation of the Nutri-plus Module · NA · completed
- NCT03295578 — Blood Glucose, Cognition and Wellbeing @ Work · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00471263 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by TNO
- Last refreshed: 23 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00471263.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing